Solid state forms of dasatinib and processes for their preparation
The present invention provides crystalline form of (R)-propylene glycol solvate of dasatinib and crystalline form of (S)-propylene glycol solvate of dasatinib.
1. A crystalline form of Dasatinib (S)-propylene glycol solvate.
2. The crystalline form of Dasatinib (S)-propylene glycol solvate characterized by PXRD pattern as shown in FIG. 2 .
3. The crystalline form according to claim 2 , characterized by an X-ray powder diffraction pattern having peaks at about 15.02, 17.93, 21.19 and 22.91±0.20 degrees 2-theta and also having peaks at about 6.03, 11.98, 18.21, 21.42, 24.10, 24.55, 26.17 and 28.05±0.20 degrees 2-theta.
4. A process for preparing Dasatinib (S)-propylene glycol solvate, comprising the steps of:
a) optionally, treating the (S)-propylene glycol solvent with antioxidant;
b) mixing dasatinib and (S)-propylene glycol solvent;
c) maintaining and isolating the propylene glycol solvate of Dasatinib; and
d) optionally, drying the propylene glycol solvate of Dasatinib.